Quote | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
Last: | $3.695 |
---|---|
Change Percent: | -0.94% |
Open: | $3.67 |
Close: | $3.73 |
High: | $3.7997 |
Low: | $3.6 |
Volume: | 18,227 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June PR Newswire CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO...
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
Message Board Posts | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
Subject | By | Source | When |
---|---|---|---|
here we go bulls news is here | db101 | investorshub | 01/31/2024 11:30:13 PM |
Price now last up | SmellMyFinger | investorshub | 01/31/2024 11:04:25 PM |
$NRBO short squeeze signal | reena969 | investorshub | 01/31/2024 7:51:08 PM |
Thoughts on where this is headed? | tw0122 | investorshub | 01/31/2024 3:47:01 PM |
The now | PennyPusher786 | investorshub | 01/31/2024 10:22:13 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June PR Newswire CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO...
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...